VLS-01 is a psychedelic drug in mid-stage clinical testing. Experts predict its trial results will be the single event that most moves stock prices and investment across the entire psychedelic industry in 2026. Optimism about laws changing or inspiring stories can only do so much — hard data from a well-run trial is what pulls in serious institutional money.
Legislative and moral narratives are already priced as optionality. Clean Phase 2b data de-risks the asset and draws institutional capital; sentiment alone will not.